CN113501846B - Eimerosamine tenofovir hemi-fumaric acid compound, crystal form, preparation method and application thereof - Google Patents
Eimerosamine tenofovir hemi-fumaric acid compound, crystal form, preparation method and application thereof Download PDFInfo
- Publication number
- CN113501846B CN113501846B CN202110648580.5A CN202110648580A CN113501846B CN 113501846 B CN113501846 B CN 113501846B CN 202110648580 A CN202110648580 A CN 202110648580A CN 113501846 B CN113501846 B CN 113501846B
- Authority
- CN
- China
- Prior art keywords
- tenofovir
- esomeprazole
- eimeric
- hemifumarate
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title claims abstract description 169
- 229960004556 tenofovir Drugs 0.000 title claims abstract description 150
- 239000013078 crystal Substances 0.000 title claims abstract description 82
- 239000001530 fumaric acid Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims abstract description 112
- 229960004770 esomeprazole Drugs 0.000 claims abstract description 112
- 150000001875 compounds Chemical class 0.000 claims description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- 239000012458 free base Substances 0.000 claims description 29
- 239000002904 solvent Substances 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 26
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 15
- 239000012296 anti-solvent Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 3
- 241000223924 Eimeria Species 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 150000004292 cyclic ethers Chemical group 0.000 claims description 3
- 150000002195 fatty ethers Chemical class 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 42
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 23
- 239000004570 mortar (masonry) Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 238000009736 wetting Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001757 thermogravimetry curve Methods 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- IACQCQDWSIQSRP-ZCFIWIBFSA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-[hydroxy(phosphonooxy)phosphoryl]oxyphosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=NC2=C1N IACQCQDWSIQSRP-ZCFIWIBFSA-N 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- -1 nucleoside monophosphate Chemical class 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960001355 tenofovir disoproxil Drugs 0.000 description 2
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- SOPCSZVJRDRWIT-MCDZGGTQSA-N OP(O)(=O)OP(O)(=O)OP(O)(O)=O.O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O.O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SOPCSZVJRDRWIT-MCDZGGTQSA-N 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000002479 acid--base titration Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Secondary Cells (AREA)
- Fuel Cell (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
The invention discloses an eimeric tenofovir hemi-fumaric acid compound with a structure shown in a formula I, a crystal form, a preparation method and application thereof. In particular to an esomeprazole tenofovir hemi-fumaric acid compound, a crystal form A, a crystal form B and a crystal form C thereof, and a preparation method and application of the crystal forms. The preparation method provided by the invention is simple and easy to implement, has good reproducibility, and the prepared esomeprazole tenofovir hemi-fumaric acid compound crystal form A has the characteristics of good solubility and small hygroscopicity, and is beneficial to preparation and storage of pharmaceutical preparations.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an eimeric tenofovir hemi-fumaric acid compound, a crystal form of the compound, and a preparation method and application of the compound.
Background
The 9- [ (R) -2- [ [ (S) - [ [ [1- (isopropoxycarbonyl) -1-methyl ] ethyl ] amino ] phenoxy phosphinyl ] methoxy ] propyl ] adenine hemi-fumarate complex (formula I) is a nucleoside reverse transcriptase inhibitor, a prodrug of tenofovir (P MPA). The PMPA structure is similar to natural nucleoside monophosphate, and is rapidly converted into an active metabolite PMPA diphosphate (PMPApp) in vivo; PMPApp competes with natural 5 'deoxyadenosine triphosphate for incorporation into viral DNA strands, but because PMPApp lacks 3' oh groups, 5',3' phosphodiester linkage cannot be performed any more, resulting in a hindered DNA strand extension, ultimately blocking viral replication. The study demonstrates that PMPA has activity against Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV).
However, PMPA contains phosphate groups, and is usually negatively charged under physiological pH conditions, and has too strong polarity to pass through biological membranes easily, so that the medicine has poor oral bioavailability, low tissue distribution coefficient and certain nephrotoxicity. Therefore, when developing the medicines, the prodrug principle is required to mask the negative charge of the phosphate group, so that the defects of the medicines are eliminated. PMPA bipyrate fumarate (tenofovirdisoproxilfumarate, TDF) was approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of HIV infection, respectively.
TDF significantly improves the pharmacokinetic properties of PMPA to some extent, but it is rapidly hydrolyzed in vivo by nonspecific esterases that are widely present in plasma, especially by intestinal mucosal epithelial cell carbonic acid esterases, releasing PMPA. The high concentration of PMPA in plasma is rapidly discharged to the outside of the body due to its poor membrane permeability, and it is difficult to maintain a sufficient concentration at the site of infection; furthermore, PMPA is a substrate for organic anion transporter (joat) of renal proximal tubule epithelial cells, and high concentration of PMPA in plasma is liable to accumulate in renal proximal tubule epithelial cells, causing a certain risk of nephrotoxicity.
The new generation of monophosphoryl monoester prodrugs overcomes the defect of TDF, is stable in blood plasma and is not easy to hydrolyze by esterase; but is absorbed into the cell; the enzyme is immediately converted into PMPA by serine protease (CATHEPSINA) and in vivo specific amidase, so that the enzyme has better tissue permeability and lymphatic tissue and cell targeting. The monophosphoryl monoester prodrug GS7340 developed by gilid corporation also has greater antiviral potency and better safety compared to 30-fold doses of TDF.
The 9- [ (R) -2- [ [ (S) - [ [ [1- (isopropoxycarbonyl) -1-methyl ] ethyl ] amino ] phenoxy phosphinyl ] methoxy ] propyl ] adenine hemi-fumaric acid complex (formula I) releases the active ingredient PMPA in the cells as does GS 7340. The 9- [ (R) -2- [ [ (S) - [ [ [1- (isopropoxycarbonyl) -1-methyl ] ethyl ] amino ] phenoxy phosphinyl ] methoxy ] propyl ] adenine hemi-fumaric acid compound (formula I) can exert the efficacy of the active ingredient PMPA of the compound more effectively than the prodrugs such as TDF and the like due to the advantages of absorption and distribution, and is beneficial to a large number of patients as a most potential new generation PMPA prodrug.
In view of the great significance of the research on the crystal forms of the medicines in clinical research, the invention comprehensively researches the esomeprazole tenofovir monofumarate and the crystal forms thereof in order to improve the solubility and solid stability of the products, reduce the storage cost, prolong the product period and improve the bioavailability of the products.
Disclosure of Invention
The inventors have found a complex of esomeprazole tenofovir and fumaric acid present in a molar ratio of 2:1. Through intensive research, the crystalline form of this complex was found. In terms of pharmaceutical development, this complex is advantageous over the salts formed by esomeprazole tenofovir or fumaric acid.
The invention provides a compound of formula I9- [ (R) -2- [ [ (S) - [ [ [1- (isopropoxycarbonyl) -1-methyl ] ethyl ] amino ] phenoxy phosphinyl ] methoxy ] propyl ] adenine and fumaric acid in a molar ratio of 2:1, which is referred to as an Eimerosamine tenofovir hemi-fumaric acid complex.
On the other hand, the esomeprazole tenofovir hemi-fumaric acid compound provided by the invention can be confirmed by nuclear magnetism and content titration. Recrystallizing the complex in different solvents or under different conditions to obtain 4 crystal forms, namely a crystal form A, a crystal form B, a crystal form C and a crystal form D. The four crystal forms verify that the molar ratio of the esomeprazole tenofovir to the fumaric acid in the crystal is 2:1 through a nuclear magnetism and content titration mode.
The esomeprazole tenofovir hemi-fumaric acid compound disclosed by the invention exists in a crystalline state or an amorphous state.
The X-ray powder diffraction pattern of the crystalline form a of the esomeprazole tenofovir hemi-fumaric acid compound has a diffraction peak at 5.1±0.2° or at 7.7±0.2°, or at 13.0±0.2°, or at 15.4±0.2°, or at 20.9±0.2°, or at 22.1±0.2°, or at 25.0±0.2°, or at 10.2±0.2°, preferably comprises any 2 to 5, or 3 to 6, or 3 to 7, more preferably comprises any 4, 6, or 8 of the above diffraction peaks;
Or alternatively
The X-ray powder diffraction pattern of the crystal form A at least comprises one or more diffraction peaks positioned in the angles of 5.1+/-0.2 DEG, 7.7+/-0.2 DEG and 13.0+/-0.2 DEG, preferably comprises two of the diffraction peaks, more preferably comprises three of the diffraction peaks; optionally, it may further comprise at least one of 15.4.+ -. 0.2 °, 20.9.+ -. 0.2 °, 22.1.+ -. 0.2 °, 25.0.+ -. 0.2 °, 10.2.+ -. 0.2 °, preferably 2, 3, 4 or 5 thereof, for example,
5.1±0.2°、7.7±0.2°;
7.7±0.2°、13.0±0.2°;
5.1±0.2°、13.0±0.2°;
5.1±0.2°、15.4±0.2°;
7.7±0.2°、20.9±0.2°;
13.0±0.2°、22.1±0.2°;
5.1±0.2°、7.7±0.2°、13.0±0.2°;
5.1±0.2°、15.4±0.2°、20.9±0.2°;
7.7±0.2°、20.9±0.2°、22.1±0.2°;
13.0±0.2°、22.1±0.2°、25.0±0.2°;
5.1±0.2°、7.7±0.2°、15.4±0.2°;
7.7±0.2°、13.0±0.2°、25.0±0.2°;
5.1±0.2°、13.0±0.2°、10.2±0.2°;
5.1±0.2°、7.7±0.2°、13.0±0.2°、15.4±0.2°;
5.1±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°;
7.7±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°;
13.0±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°;
5.1±0.2°、7.7±0.2°、15.4±0.2°、20.9±0.2°;
5.1±0.2°、13.0±0.2°、22.1±0.2°、25.0±0.2°;
7.7±0.2°、13.0±0.2°、25.0±0.2°、10.2±0.2°;
Or alternatively
The X-ray powder diffraction pattern of form a optionally further comprises one or more diffraction peaks at 2Θ of 10.5±0.2°, 10.8±0.2°, 16.1±0.2°, 17.0±0.2°, 19.6±0.2°, 20.4±0.2° and 29.2±0.2°; preferably at least any of 2 to 3, or 4 to 5, or 6 to 7; further preferably, any of 2, 3, 4, 5, 6, 7 are included; for example, the number of the cells to be processed,
10.5±0.2°、10.8±0.2°、16.1±0.2°;
10.8±0.2°、16.1±0.2°、17.0±0.2°;
17.0±0.2°、19.6±0.2°、20.4±0.2°;
10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°;
10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°;
16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2°;
10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2°;
10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2°、29.2±0.2°;
10.5±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2°、29.2±0.2°;
Or alternatively
The X-ray powder diffraction pattern of form a has diffraction peaks at 5.1±0.2°、7.7±0.2°、13.0±0.2°、1 5.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0. 2°、16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2° and 29.2 + 0.2 deg. 2 theta, preferably, including those wherein optionally 4, 5, 6, 8 or 10 have diffraction peaks, e.g.,
5.1±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
7.7±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°;
13.0±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°;
5.1±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°;
7.7±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°;
13.0±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
5.1±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°;
7.7±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°;
13.0±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°;
5.1±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、 10.5±0.2°、10.8±0.2°;
7.7±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、 16.1±0.2°、17.0±0.2°;
13.0±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、 17.0±0.2°、19.6±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、 10.8±0.2°、16.1±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、 16.1±0.2°、17.0±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°;
5.1±0.2°、7.7±0.2°、13.0±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、 25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
7.7±0.2°、13.0±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、 10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°;
13.0±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、 10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、 10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、 16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、 17.0±0.2°、19.6±0.2°、20.4±0.2°、29.2±0.2°.
Further preferably, form a has an X-ray powder diffraction pattern substantially as shown in fig. 1, a DSC profile substantially as shown in fig. 1A, a TGA profile substantially as shown in fig. 1B, and a 1 HNMR profile substantially as shown in fig. 1C.
Still more preferably, the DSC profile of form A has an endothermic peak at about 92 ℃, the TGA profile of form A has substantially no weight loss prior to decomposition, and the 1 HNMR profile of form A shows a semi-fumonic acid complex.
The X-ray powder diffraction pattern of the crystalline form B of the esomeprazole tenofovir hemi-fumarate complex has a diffraction peak at 2θ of 4.4±0.2°, or has a diffraction peak at 6.6±0.2°, or has a diffraction peak at 7.7±0.2°, or has a diffraction peak at 13.0±0.2°, or has a diffraction peak at 15.4±0.2°, or has a diffraction peak at 22.1±0.2°, or has a diffraction peak at 23.2±0.2°, or has a diffraction peak at 26.7±0.2°, preferably comprises any 2 to 5, or 3 to 6, or 3 to 8, more preferably comprises any 4, 6 or 8 of the above diffraction peaks;
Or alternatively
The X-ray powder diffraction pattern of the crystal form B comprises one or more diffraction peaks in the angles of 4.4+/-0.2 DEG, 6.6+/-0.2 DEG and 7.7+/-0.2 DEG, preferably two of the diffraction peaks, more preferably three diffraction peaks; optionally, it may further comprise at least one of the angles of 26.7.+ -. 0.2, 4.9.+ -. 0.2 °, 10.5.+ -. 0.2 °, 13.3.+ -. 0.2 °, 17.0.+ -. 0.2 ℃ and preferably 2, 3, 4 or 5 thereof, for example,
4.4±0.2°、6.6±0.2°;
6.6±0.2°、7.7±0.2°;
4.4±0.2°、7.7±0.2°;
4.4±0.2°、26.7±0.2°;
6.6±0.2°、4.9±0.2°;
7.7±0.2°、10.5±0.2°;
4.4±0.2°、6.6±0.2°、7.7±0.2°;
4.4±0.2°、26.7±0.2、4.9±0.2°;
6.6±0.2°、4.9±0.2°、10.5±0.2°;
7.7±0.2°、10.5±0.2°、13.3±0.2°;
4.4±0.2°、6.6±0.2°、13.3±0.2°;
6.6±0.2°、7.7±0.2°、17.0±0.2°;
4.4±0.2°、7.7±0.2°、10.5±0.2°;
4.4±0.2°、26.7±0.2、4.9±0.2°、10.5±0.2°;
6.6±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°;
7.7±0.2°、10.5±0.2°、13.3±0.2°、17.0±0.2°;
4.4±0.2°、6.6±0.2°、26.7±0.2、4.9±0.2°;
6.6±0.2°、7.7±0.2°、4.9±0.2°、10.5±0.2°;
4.4±0.2°、7.7±0.2°、10.5±0.2°、13.3±0.2°;
4.4±0.2°、6.6±0.2°、7.7±0.2°、17.0±0.2°;
The X-ray powder diffraction pattern of form B optionally further comprises one or more diffraction peaks at 2Θ of 4.9±0.2°, 10.5±0.2°, 13.3±0.2°, 17.0±0.2°, 20.4±0.2°, 20.9±0.2°, and 22.8±0.2°; preferably at least any of 2 to 3, or 4 to 5, or 6 to 7; further preferably, any of 2, 3, 4, 5, 6, 7 are included; for example, the number of the cells to be processed,
4.9±0.2°、10.5±0.2°、13.3±0.2°;
10.5±0.2°、13.3±0.2°、17.0±0.2°;
13.3±0.2°、17.0±0.2°、20.4±0.2°;
4.9±0.2°、10.5±0.2°、13.3±0.2°、17.0±0.2°;
10.5±0.2°、13.3±0.2°、17.0±0.2°、20.4±0.2°;
13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2°;
4.9±0.2°、10.5±0.2°、13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2°;
4.9±0.2°、13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2°、22.8±0.2°;
10.5±0.2°、13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2°、22.8±0.2°;
Or alternatively
The X-ray powder diffraction pattern of form B has diffraction peaks at 4.4±0.2°、6.6±0.2°、7.7±0.2°、13. 0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、 13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2° and 22.8±0.2°, preferably including those having diffraction peaks at optionally 4,5, 6, 8 or 10, for example,
4.4±0.2°、13.0±0.2°、15.4±0.2°、22.1±0.2°;
6.6±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°;
7.7±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°;
15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°;
22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°;
23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
4.4±0.2°、13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°;
6.6±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°;
7.7±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°;
13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°;
15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°;
22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
4.4±0.2°、13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°;
6.6±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
7.7±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°;
13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°;
15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°;
4.4±0.2°、13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、 4.9±0.2°、10.5±0.2°;
6.6±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、 13.3±0.2°、17.0±0.2°;
7.7±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°、17.0±0.2°、20.4±0.2°;
13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、 10.5±0.2°、13.3±0.2°;
15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、1 3.3±0.2°、17.0±0.2°;
22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°、 17.0±0.2°、20.4±0.2°;
4.4±0.2°、6.6±0.2°、7.7±0.2°、13.0±0.2°、15.4±0.2°、22.1±0.2°、 23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
6.6±0.2°、7.7±0.2°、13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、 26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°;
7.7±0.2°、13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、 4.9±0.2°、10.5±0.2°、13.3±0.2°、17.0±0.2°;
13.0±0.2°、15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、 10.5±0.2°、13.3±0.2°、17.0±0.2°、20.4±0.2°;
15.4±0.2°、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、 13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2°;
、22.1±0.2°、23.2±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°、 17.0±0.2°、20.4±0.2°、20.9±0.2°、22.8±0.2°.
Further preferably, form B has an X-ray powder diffraction pattern substantially as shown in fig. 2, a DSC pattern substantially as shown in fig. 2A, a TGA pattern substantially as shown in fig. 2B, and a 1 HNMR pattern substantially as shown in fig. 2C.
Still more preferably, the DSC profile of form B has an endothermic peak at about 95 ℃, the TGA profile of form B has substantially no weight loss prior to decomposition, and the 1 HNMR profile of form B shows a semi-fumonic acid complex.
The X-ray powder diffraction pattern of the crystalline form C of the esomeprazole tenofovir hemi-fumarate complex has a diffraction peak at 5.0±0.2° or at 7.8±0.2°, or at 13.1±0.2°, or at 14.4±0.2°, or at 18.1±0.2°, or at 20.5±0.2°, or at 21.0±0.2, or at 22.2±0.2°, preferably comprises any of the above diffraction peaks at 2 to 5, or at 3 to 6, or at 3 to 8, more preferably comprises any of 4, 6, or 8;
Or alternatively
An X-ray powder diffraction pattern of form C comprises one or more diffraction peaks at 5.0±0.2°, 7.8±0.2°, 13.1±0.2°, preferably two of the peaks, more preferably three of the peaks; optionally, it may further comprise at least one of the angles of 14.4.+ -. 0.2 °, 18.1.+ -. 0.2 °, 20.5.+ -. 0.2 °, 21.0.+ -. 0.2 °, 22.2.+ -. 0.2 °, preferably 2, 3,4 or 5 thereof, for example,
5.0±0.2°、7.8±0.2°;
7.8±0.2°、13.1±0.2°;
5.0±0.2°、13.1±0.2°;
5.0±0.2°、14.4±0.2°;
7.8±0.2°、18.1±0.2°;
13.1±0.2°、20.5±0.2°;
5.0±0.2°、7.8±0.2°、13.1±0.2°;
5.0±0.2°、20.5±0.2°、21.0±0.2°;
7.8±0.2°、18.1±0.2°、20.5±0.2°;
13.1±0.2°、14.4±0.2°、18.1±0.2°;
5.0±0.2°、7.8±0.2°、14.4±0.2°;
7.8±0.2°、13.1±0.2°、20.5±0.2°;
5.0±0.2°、13.1±0.2°、20.5±0.2°;
5.0±0.2°、7.8±0.2°、13.1±0.2°、14.4±0.2°;
7.8±0.2°、13.1±0.2°、14.4±0.2°、18.1±0.2°;
5.0±0.2°、13.1±0.2°、18.1±0.2°、20.5±0.2°;
5.0±0.2°、7.8±0.2°、13.1±0.2°、21.0±0.2°;
5.0±0.2°、14.4±0.2°、18.1±0.2°、20.5±0.2°;
7.8±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°;
13.1±0.2°、20.5±0.2°、21.0±0.2°、22.2±0.2°;
The X-ray powder diffraction pattern of form C optionally further comprises one or more diffraction peaks at 9.7±0.2°, 10.6±0.2°, 11.5±0.2°, 15.5±0.2°, 16.3±0.2°, 17.1±0.2° and 19.8±0.2°; preferably at least any of 2 to 3, or 4 to 5, or 6 to 7; further preferably, any of 2, 3, 4, 5, 6, 7 are included; for example, the number of the cells to be processed,
9.7±0.2°、10.6±0.2°、11.5±0.2°;
10.6±0.2°、11.5±0.2°、15.5±0.2°;
11.5±0.2°、15.5±0.2°、16.3±0.2°;
9.7±0.2°、10.6±0.2°、11.5±0.2°、15.5±0.2°;
10.6±0.2°、11.5±0.2°、15.5±0.2°、16.3±0.2°;
11.5±0.2°、15.5±0.2°、16.3±0.2°、17.1±0.2°;
9.7±0.2°、10.6±0.2°、11.5±0.2°、15.5±0.2°、16.3±0.2°、17.1±0.2°;
10.6±0.2°、11.5±0.2°、15.5±0.2°、16.3±0.2°、17.1±0.2°、19.8±0.2°;
9.7±0.2°、11.5±0.2°、15.5±0.2°、16.3±0.2°、17.1±0.2°、19.8±0.2°;
Or alternatively
The X-ray powder diffraction pattern of form C has diffraction peaks at 5.0±0.2°、7.8±0.2°、13.1±0.2°、1 4.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0. 2°、13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2° and 22.8±0.2° in 2θ, preferably, including those having diffraction peaks at optionally 4, 5, 6, 8 or 10, for example,
5.0±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°;
7.8±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°;
13.1±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°;
18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°;
20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°;
5.0±0.2°、14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°;
7.8±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°;
13.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°;
14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°;
18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°;
20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
5.0±0.2°、14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°;
7.8±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°;
13.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°;
18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°;
5.0±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、 10.5±0.2°、13.3±0.2°;
7.8±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、 13.3±0.2°、17.0±0.2°;
13.1±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°、 17.0±0.2°、20.4±0.2°;
14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、 10.5±0.2°、13.3±0.2°;
18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、 13.3±0.2°、17.0±0.2°;
20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°、 17.0±0.2°、20.4±0.2°;
5.0±0.2°、7.8±0.2°、13.1±0.2°、14.4±0.2°、18.1±0.2°、20.5±0.2°、 21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°;
7.8±0.2°、13.1±0.2°、14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、 26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°;
13.1±0.2°、14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4. 9±0.2°、10.5±0.2°、13.3±0.2°、17.0±0.2°;
14.4±0.2°、18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、 10.5±0.2°、13.3±0.2°、17.0±0.2°、20.4±0.2°;
18.1±0.2°、20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、 13.3±0.2°、17.0±0.2°、20.4±0.2°、20.9±0.2°;
20.5±0.2°、21.0±0.2°、26.7±0.2°、4.9±0.2°、10.5±0.2°、13.3±0.2°、 17.0±0.2°、20.4±0.2°、20.9±0.2°、22.8±0.2°.
Further preferably, form C has an X-ray powder diffraction pattern substantially as shown in fig. 3, a DSC pattern substantially as shown in fig. 3A, and 1 HNMR pattern substantially as shown in fig. 3B.
Still more preferably, the DSC profile of form C has an endothermic peak at about 83℃and the 1 HNMR profile of form C shows a hemi-fumaric complex.
The X-ray powder diffraction pattern of the crystalline form D of the esomeprazole tenofovir hemi-fumaric acid compound has a diffraction peak at 2θ of 4.8±0.2°, or has a diffraction peak at 6.9±0.2°, or has a diffraction peak at 7.8±0.2°, or has a diffraction peak at 13.0±0.2°, or has a diffraction peak at 14.4±0.2, or has a diffraction peak at 20.4±0.2, or has a diffraction peak at 22.1±0.2, or has a diffraction peak at 25.0±0.2, preferably comprises any 2 to 5, or 3 to 6, or 3 to 8, more preferably comprises any 4, 6, or 8 of the above diffraction peaks.
The X-ray powder diffraction pattern of the crystal form D provided by the invention is 4.8+/-0.2 degrees in 2 theta,
Having diffraction peaks at 6.9 + -0.2 deg., 7.8 + -0.2 deg., and 13.0 + -0.2 deg., preferably, further comprising having characteristic peaks at 2θ deg.s of 1.4 + -0.2, 20.4 + -0.2, 22.1 + -0.2, and 25.0 + -0.2 deg., more preferably, further comprising having diffraction peaks at 2θ's of 9. 3±0.2°、9.7±0.2°、10.6±0.2°、15.5±0.2°、16.2±0.2°、18.0±0.2°、19.7±0.2°、 20.9±0.2°、22.9±0.2°、24.2±0.2°、25.4±0.2°、26.1±0.2°、26.6±0.2°、 28.7±0.2° and 29.3 + -0.2 deg..
Further preferably, the X-ray powder diffraction pattern is substantially as shown in FIG. 4, the DSC pattern is substantially as shown in FIG. 4A, and the 1 HNMR pattern is substantially as shown in FIG. 4B.
Still more preferably, the DSC profile of form D has an endothermic peak at about 84℃and the 1 HNMR profile of form D shows a hemi-fumaric complex.
In another aspect, the present invention provides an innovative method of preparing a hemi-fumaric acid complex: according to the structural characteristics of Shan Fuma acid salt, introducing free base with the same mole as that of monofumarate, and reacting with exposed carboxyl groups on the monofumarate to prepare the hemi-fumarate. Based on this, the invention provides methods for the preparation of form a and form B.
The preparation method of the esomeprazole tenofovir hemifumarate compound crystal form A comprises the following steps:
① Mixing the esomeprazole tenofovir monofumarate and the esomeprazole tenofovir free base with a solvent at a certain temperature;
② Adding an antisolvent into the solution system to crystallize the solution system;
③ Stirring, filtering and collecting solids to obtain the crystalline form A of the esomeprazole tenofovir hemifumarate compound.
The temperature condition in the step ① is 55-70 ℃, preferably 60-65 ℃ and most preferably 65 ℃ in the preparation method of the esomeprazole tenofovir half-fumaric acid compound crystal form A; the molar ratio of the eimeric tenofovir monofumarate to the eimeric tenofovir free base is 1:1 to 1:3, preferably 1:1.1 to 1:2, most preferably 1:1.2 to 1:1.5; the mass volume ratio of the mixture of the eimeric tenofovir monofumarate and the eimeric tenofovir free base to the solvent is 1g to 2ml to 1g to 8ml, preferably 1g to 3ml to 1g to 6ml, and most preferably 1g to 4ml; the solvent is selected from one of cyclic ethers, preferably tetrahydrofuran, 2-methyltetrahydrofuran, 1, 4-dioxane, most preferably tetrahydrofuran; the reaction time is 1 to 6 hours, preferably 2 to 5 hours, most preferably 2 to 3 hours.
The preparation method of the esomeprazole tenofovir hemifumarate compound crystal form A comprises the step ②, wherein the antisolvent is selected from fatty ether or alkane, preferably one of methyl tertiary butyl ether, isopropyl ether and n-heptane, and most preferably isopropyl ether; the amount of antisolvent used is 2 to 7 times, preferably 3 to 6 times, most preferably 4 to 5 times the amount of solvent used in step ①.
According to the preparation method of the esomeprazole tenofovir hemifumarate compound crystal form A, the stirring time in the step ③ is 5-24 hours, preferably 8-20 hours and most preferably 10-18 hours.
In another aspect, a method for preparing crystalline form B of an esomeprazole tenofovir hemifumarate complex comprises the steps of:
① Mixing the esomeprazole tenofovir monofumarate and the esomeprazole tenofovir free base with a solvent at a certain temperature;
② Adding an antisolvent into the solution system to crystallize the solution system;
③ Stirring, filtering and collecting solids to obtain the crystalline form B of the esomeprazole tenofovir hemifumarate compound.
The preparation method of the esomeprazole tenofovir hemifumarate compound crystal form B comprises the following steps that ① is carried out at a temperature of 0-50 ℃, preferably 10-40 ℃ and most preferably 20-30 ℃; the molar ratio of the eimeric tenofovir monofumarate to the eimeric tenofovir free base is 1:1 to 1:3, preferably 1:1.1 to 1:2, most preferably 1:1.2 to 1:1.5; the mass volume ratio of the mixture of the esomepiride monofumarate and the esomepiride free base to the solvent is 1g, 2ml to 1g, 8ml, preferably 1g, 3ml to 1g, 6ml, most preferably 1g, 4ml; the solvent is selected from cyclic ether, preferably tetrahydrofuran, 2-methyltetrahydrofuran, 1, 4-dioxane, and most preferably tetrahydrofuran; the reaction time is 1 to 6 hours, preferably 2 to 5 hours, most preferably 2 to 3 hours.
The preparation method of the esomeprazole tenofovir hemifumarate compound crystal form B comprises the step ②, wherein the antisolvent is selected from fatty ether or alkane, preferably one of methyl tertiary butyl ether, isopropyl ether and n-heptane, and most preferably isopropyl ether; the amount of antisolvent used is 2 to 7 times, preferably 3 to 6 times, most preferably 4 to 5 times the amount of solvent used in step ①.
According to the preparation method of the esomeprazole tenofovir hemifumarate compound crystal form B, the stirring time in the step ③ is 5-24 hours, preferably 8-20 hours and most preferably 10-18 hours.
In another aspect, a method for preparing crystalline form C of an esomeprazole tenofovir hemifumarate complex comprises the steps of:
① Weighing the esomeprazole tenofovir free base and fumaric acid in a mortar according to a molar ratio of 2:1;
② Adding solvent into a mortar for wetting and grinding;
③ And collecting the solid to obtain the crystalline form C of the esomeprazole tenofovir hemifumarate complex.
According to the preparation method of the esomeprazole tenofovir half fumaric acid compound crystal form C, the mass volume ratio of a mixture of the esomeprazole tenofovir free base and fumaric acid to a solvent in the step ② is 1g:2 ml-1 g:8ml, preferably 1g:3 ml-1 g:6ml, and most preferably 1g:4 ml-1 g:5ml; step ② solvent is selected from the group consisting of fatty alcohols, preferably C 1~C3 alcohol solvents, most preferably ethanol.
On the other hand, the invention also provides a preparation method of the esomeprazole tenofovir hemi-fumaric acid compound crystal form D, which comprises the following steps:
① Weighing the esomeprazole tenofovir free base and fumaric acid in a mortar according to a molar ratio of 2:1;
② Adding solvent into a mortar for wetting and grinding;
③ And collecting the solid to obtain the crystalline form D of the esomeprazole tenofovir hemifumarate compound.
In accordance with the above-described steps,
In a preferred embodiment of the present invention, the mass to volume ratio of the mixture of esomeprazole tenofovir free base and fumaric acid to the solvent of step ② is 1g:2ml to 1g:8ml, preferably 1g:3ml to 1g:6ml, most preferably 1g:4 ml to 1g:5ml; step ② the solvent is selected from the group consisting of fatty alcohols, preferably C 4~C7, alcoholic solvents, most preferably n-hexanol.
In another aspect, the invention relates to a pharmaceutical composition comprising a therapeutically effective dose of a crystalline form of an esomeprazole tenofovir hemifumarate complex and one or more pharmaceutically acceptable carriers, diluents or excipients. Pharmaceutically acceptable carriers refer to: one or more compatible solid or liquid fill or gel materials which are suitable for human use and must be of sufficient purity and low enough toxicity. Wherein compatibility herein means that the components of the composition are capable of being mixed with the active ingredients of the present invention and with each other without significantly reducing the efficacy of the active ingredients; pharmaceutically acceptable carriers include cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate and the like, solid lubricants such as stearic acid, magnesium stearate and the like, vegetable oils such as soybean oil, castor oil, peanut oil, olive oil and the like, polyols such as propylene glycol, glycerin, mannitol, sorbitol and the like, emulsifying agents such as tween series, wetting agents such as sodium dodecyl sulfate, gelatin, talc, colorants, flavoring agents, stabilizers and the like.
The pharmaceutical composition may be a tablet or a capsule.
In another aspect, the present invention relates to the use of crystalline forms of the esomeprazole tenofovir hemifumarate complex, or a pharmaceutically acceptable composition thereof, in the manufacture of a medicament for the treatment of hepatitis, preferably chronic hepatitis b.
The crystalline form of the esomeprazole tenofovir hemifumarate has the characteristics of good solubility, small hygroscopicity and high bioavailability, is beneficial to the processing of medicines and the use of the same in a medicine composition, and the preparation method is simple, convenient and easy to implement and has good reproducibility.
Drawings
Figure 1 is an X-ray diffraction pattern of crystalline form a of the esomeprazole tenofovir hemifumarate complex.
Fig. 1A is a DSC profile of crystalline form a of the esomeprazole tenofovir hemifumarate complex.
Fig. 1B is a TGA profile of crystalline form a of the esomeprazole tenofovir hemifumarate complex.
Fig. 1C is a 1 HNMR profile of esomeprazole tenofovir hemifumarate complex form a.
Figure 2 is an X-ray diffraction pattern of crystalline form B of the esomeprazole tenofovir hemifumarate complex.
Fig. 2A is a DSC profile of crystalline form B of the esomeprazole tenofovir hemifumarate complex.
Fig. 2B is a TGA profile of crystalline form B of the esomeprazole tenofovir hemifumarate complex.
Fig. 2C is a 1 HNMR profile of esomeprazole tenofovir hemifumarate complex form B.
Figure 3 is an X-ray diffraction pattern of crystalline form C of the esomeprazole tenofovir hemifumarate complex.
Fig. 3A is a DSC profile of crystalline form C of the esomeprazole tenofovir hemifumarate complex.
Fig. 3B is a 1 HNMR profile of esomeprazole tenofovir hemifumarate complex form C.
Fig. 4 is an X-ray diffraction pattern of crystalline form D of the esomeprazole tenofovir hemifumarate complex.
Fig. 4A is a DSC profile of crystalline form D of the esomeprazole tenofovir hemifumarate complex.
Fig. 4B is a 1 HNMR profile of esomeprazole tenofovir hemifumarate complex form D.
Fig. 5 is a dynamic moisture adsorption profile of crystalline form a of the esomeprazole tenofovir hemifumarate complex.
Fig. 6 is a dissolution profile of crystalline form a of esomeprazole tenofovir monofumarate and esomeprazole tenofovir hemifumarate complex.
Detailed Description
The following describes in further detail the embodiments of the present invention with reference to the drawings and examples. The following examples are illustrative of the invention and are not intended to limit the scope of the invention.
Example 1: preparation of esomeprazole tenofovir hemifumarate compound crystal form A
3G of esomeprazole tenofovir monofumarate and 3g of esomeprazole tenofovir free base are weighed and mixed with 18mL of tetrahydrofuran, the system temperature is controlled to be 60 ℃, stirring is started, the system is clarified, stirring is carried out for 2h under the heat preservation condition, 54mL of isopropyl ether is added into the system under the heat preservation condition, stirring is carried out for 12h, filtering is carried out, and the product is dried by blowing at 45 ℃ for 2h, so that the crystal form A of the esomeprazole tenofovir semi-fumaric acid compound with the molar yield of 92% and the purity of 98.3% is obtained.
Example 2: preparation of esomeprazole tenofovir hemifumarate compound crystal form A
6G of esomeprazole tenofovir monofumarate and 6.5g of esomeprazole tenofovir free base are weighed and mixed with 50 mL g of 1, 4-dioxane, the system temperature is controlled to be 65 ℃, stirring is started, the system is clarified, stirring is kept at 3: 3h, 120mL of methyl tertiary butyl ether is added to the system under the condition of keeping the temperature, stirring is carried out for 16 hours, filtering is carried out, and the product is placed at 40 ℃ for forced air drying for 18 hours, so that the crystal form A of the esomepiride hemifumarate compound is obtained, the molar yield is 91%, and the purity is 98.4%.
Example 3: preparation of esomeprazole tenofovir hemifumarate compound crystal form A
1G of esomeprazole tenofovir monofumarate and 1.1g of esomeprazole tenofovir free base are weighed and mixed with 10 mL tetrahydrofuran, the system temperature is controlled to be 60 ℃, stirring is started, the system is clarified, the temperature is kept for 2.5h, 45mL of n-heptane is added to the system under the heat-preserving condition, stirring is carried out for 12h, filtering is carried out, and the product is placed at 45 ℃ for blast drying for 24h, so that the crystal form A of the esomeprazole tenofovir semi-fumaric acid compound is obtained, the molar yield is 90%, and the purity is 9.8%.
Example 4: preparation of esomeprazole tenofovir hemifumarate compound crystal form A
2G of esomeprazole tenofovir monofumarate and 2g of esomeprazole tenofovir free base are weighed and mixed with 12mL of 1, 4-dioxane, the system temperature is controlled to be 55 ℃, stirring is started, the system is clarified, stirring is carried out for 2h at a temperature which is equal to or higher than that of the system, 40mL of methyl tertiary butyl ether is added to the system under the heat-preserving condition, stirring is carried out for 10h, filtering is carried out, and the product is dried for 20h at 40 ℃ by blowing, so that the crystal form A of the esomeprazole tenofovir half fumaric acid compound is obtained, the molar yield is 91%, and the purity is 98.3%.
Example 5: preparation of esomeprazole tenofovir hemifumarate compound crystal form A
Weighing 4g of esomeprazole tenofovir monofumarate and 4.5g of esomeprazole tenofovir free base, mixing with 40 mL g of tetrahydrofuran, controlling the temperature of the system to be 62 ℃, starting stirring, clarifying the system, stirring for 4h at a constant temperature, adding 180mL of isopropyl ether into the system under a constant temperature condition, stirring for 14h, filtering, and drying the product at 45 ℃ by blowing for 18h to obtain the crystal form A of the esomeprazole tenofovir hemifumarate compound with the molar yield of 92% and the purity of 9.6%.
Example 6: preparation of esomeprazole tenofovir hemifumarate compound crystal form B
3G of esomeprazole tenofovir monofumarate and 3.2g of esomeprazole tenofovir free base are weighed and mixed with 20 mL tetrahydrofuran, the system temperature is controlled to be 25 ℃, stirring is started, the system is clarified, the temperature is kept and stirred for 2 hours, 70mL of isopropyl ether is added to the system under the condition of keeping the temperature, stirring is carried out for 14 hours, filtering is carried out, and the product is dried by blowing at 30 ℃ for 24 hours, so that the crystal form B of the esomeprazole tenofovir semi-fumaric acid compound is obtained, the molar yield is 91%, and the purity is 98.4%.
Example 7: preparation of esomeprazole tenofovir hemifumarate compound crystal form B
1.5G of esomeprazole tenofovir monofumarate and 1.7g of esomeprazole tenofovir free base are weighed and mixed with 15 mL of 1, 4-dioxane, the temperature of the system is controlled to be 30 ℃, stirring is started, the system is clarified, the system is stirred for 2h in a heat preservation manner, 45mL of n-heptane is added to the system under the heat preservation condition, stirring is carried out for 12h, filtering is carried out, and the product is dried for 20h at 30 ℃ in a blasting manner, so that the crystal form B of the esomeprazole tenofovir hemifumarate compound is obtained, the molar yield is 90%, and the purity is 98.7%.
Example 8: preparation of esomeprazole tenofovir hemifumarate compound crystal form C
1G of esomeprazole tenofovir disoproxil free base and 0.12g of fumaric acid are weighed in a mortar, 4mL of ethanol is added for wetting and grinding, and the esomeprazole tenofovir hemi-fumaric acid compound crystal form C is obtained.
Example 9: preparation of esomeprazole tenofovir hemifumarate compound crystal form C
2G of esomeprazole tenofovir free base and 0.24g of fumaric acid are weighed in a mortar, 5.5mL of isopropyl alcohol is added for wetting and grinding, and the esomeprazole tenofovir hemi-fumaric acid compound crystal form C is obtained.
Example 10: preparation of esomeprazole tenofovir hemifumarate compound crystal form D
0.5G of esomeprazole tenofovir free base and 0.06g of fumaric acid are weighed in a mortar, 2mL of n-hexylalcohol is added for wetting and grinding, and the esomeprazole tenofovir hemi-fumaric acid compound crystal form D is obtained.
Example 11: preparation of esomeprazole tenofovir hemifumarate compound crystal form D
2G of esomeprazole tenofovir free base and 0.24g of fumaric acid are weighed in a mortar, 4.5mL of n-butyl alcohol is added for wetting and grinding, and the esomeprazole tenofovir hemi-fumaric acid compound crystal form D is obtained.
Experimental example 12: structure confirmation of esomeprazole tenofovir hemifumarate complex
The structural formula of the esomeprazole tenofovir hemi-fumaric acid compound is shown as formula II:
(1) Hydrogen nuclear magnetic resonance spectroscopy (1 H-NMR): 10mg of the crystal form A is weighed and placed in a nuclear magnetic tube with 5mm, 500 mu L of deuterated dimethyl sulfoxide is used for dissolving and uniformly mixing, a Bruker AVANCE400MHz full-digital nuclear magnetic resonance spectrometer is used for detecting a sample, a hydrogen nuclear magnetic resonance spectrogram is shown in figure 1C, and related data are shown in the following table:
chemical shift (ppm) | Multiple of | Proton number | Proton attribution | Remarks |
1.08-1.10 | d | 3 | H-22 | J=6.2Hz |
1.12-1.14 | m | 6 | H-20,H-20’ | / |
1.29 | s | 3 | H-29 | / |
1.32 | s | 3 | H-29’ | / |
3.83-3.85 | m | 1 | H-13a | / |
3.86-3.88 | m | 1 | H-13b | / |
3.97-4.01 | m | 1 | H-11 | / |
4.16-4.21 | m | 1 | H-10a | / |
4.26-4.31 | m | 1 | H-10b | / |
4.81-4.87 | m | 1 | H-19 | / |
5.28-5.31 | d | 1 | 15-NH | J=10.7Hz |
6.64 | s | 1 | H-31,H-31’ | / |
7.07-7.10 | d | 2 | H-26,H-26’ | J=8.0Hz |
7.13 | t | 1 | H-28 | J=7.4Hz |
7.26 | s | 2 | 21-NH2 | / |
7.30 | t | 2 | H-27,H-27’ | J=7.8Hz |
8.13 | s | 1 | H-8 | / |
8.14 | s | 1 | H-6 | / |
13.03 | br | 1 | 33-OH,33’-OH | / |
The results showed a set of single peaks at delta 6.64ppm, corresponding to 1 proton, each 1/2 proton attributed to the olefin at the 31/31' position, confirming a 2:1 molar ratio of esomeprazole tenofovir to fumaric acid in the crystals.
The hydrogen nuclear magnetic resonance spectrograms of the crystal form B, the crystal form C and the crystal form D are respectively shown in the figure 2C, the figure 3B and the figure 4B, and are consistent with the hydrogen nuclear magnetic resonance spectrograms of the crystal form A, so that the molar ratio of the esomepiridine tenofovir to the fumaric acid in the crystal is proved to be 2:1.
(2) Acid-base titration method for measuring fumaric acid content: 0.2g of form A, form B, form C and form D are weighed respectively, precisely weighed and dissolved by adding 40mL of methanol. Potentiometric titration (rule 0701 in the fourth edition of China pharmacopoeia 2015) was used, titration was performed with sodium hydroxide titration solution (0.1 mol/L), and the titration result was corrected by blank test. The titrant of sodium hydroxide (0.1 mol/L) per 1ml corresponds to 5.80mg of C 4H4O4, the results are shown in the following Table:
Crystal form A | Crystal form B | Crystal form C | Crystal form D | |
Fumaric acid content | 10.6% | 10.6% | 10.7% | 10.6% |
The result shows that the theoretical content of fumaric acid in the esomeprazole tenofovir half-fumaric acid compound is 10.6%, the actual detection result of the content of 4 crystal forms of fumaric acid is basically consistent with the theoretical value, and the mol ratio of the esomeprazole tenofovir to the fumaric acid in the crystal is 2:1.
Experimental example 13: solubility of
The solubility of the crystalline form a of the idefenamide tenofovir disoproxil monofumarate and the idefenamide tenofovir hemifumarate complex were measured separately with reference to the solubility measurement method provided in pharmacopoeia of the people's republic of 2020 edition, and the results are shown in the following table:
Sample type | Amount of water required to dissolve 1g of solute | Solubility of |
Eimerosamine tenofovir monofumarate | 52mL | Slightly soluble |
Eimerosamine tenofovir hemifumarate complex crystal form A | 24mL | Dissolving |
The result shows that the solubility of the crystal form A of the esomeprazole tenofovir hemifumarate compound is better than that of the esomeprazole tenofovir monofumarate, so that the compound has better bioavailability.
Experimental example 14: moisture permeability
The moisture absorption and weight gain of the crystalline form a of the eimeria tenofovir Wei Ban fumaric acid compound under different humidity conditions were examined by a dynamic moisture absorber (DVS INTRINSIC), and the results are shown in fig. 5.
The results show that the crystalline form a of the esomeprazole tenofovir hemifumarate complex has less hygroscopicity and is a desirable feature for pharmaceutical formulations.
Experimental example 15: interconversion relationship of forms A and B
(1) Phase change of solvent medium
Research shows that under the condition that no crystal seed is additionally added in the same crystallization system, the crystal form B is easy to obtain at low temperature, the crystal form A is easy to obtain at high temperature, the competition condition of the crystal forms A and B which are mixed with equal quality in a crystallization mother liquor system consisting of tetrahydrofuran/isopropyl ether is inspected, and the result is shown in the following table:
Raw material type | Crystallization mother liquor system | Temperature (temperature) | Crystal form |
Crystal form A/B (250 mg/250 mg) | THF/IPE(5mL/15mL) | 25℃ | Crystal form B |
Crystal form A/B (250 mg/250 mg) | THF/IPE(5mL/15mL) | 45℃ | Crystal form A/B |
Crystal form A/B (250 mg/250 mg) | THF/IPE(5mL/15mL) | 55℃ | Crystal form A/B |
Crystal form A/B (250 mg/250 mg) | THF/IPE(5mL/15mL) | 75℃ | Crystal form A |
The result shows that the crystal form B is a dominant crystal form at low temperature in the crystallization system, and the high Wen Xiajing type A is a dominant crystal form.
(2) Solid phase transition
The crystal form transformation conditions of the equal-mass mixed crystal forms A and B under the condition of different temperature blast drying are examined, and the results are shown in the following table:
Raw material type | Drying temperature | Crystal form |
Crystal form A/B (250 mg/250 mg) | 30℃ | Crystal form A/B |
Crystal form A/B (250 mg/250 mg) | 40℃ | Crystal form A/B |
Crystal form A/B (250 mg/250 mg) | 50℃ | Crystal form A/B |
Crystal form A/B (250 mg/250 mg) | 60℃ | Crystal form A |
The results show that the crystal form B can be converted into the crystal form A under the high-temperature condition.
Experimental example 16: dissolution rate
Raw and auxiliary materials | Prescription weight percentage |
Active ingredient | 24.1% |
Lactose and lactose | 30.6% |
Carboxymethylcellulose calcium | 25.4% |
Talc powder | 17.4% |
Glyceryl behenate | 2.5% |
Taking into account the dissolution rates of the crystalline form a of the eimeric tenofovir monofumarate and the crystalline form a of the eimeric tenofovir hemifumarate in the powder direct compression formulation, mixing the raw materials and the auxiliary materials in an equal-increment manner according to the formulation shown in the table above, tabletting with a DP301 single-punch tablet press to 25mg, and taking into account the dissolution rates of the obtained tablets in a dissolution medium (ph=4.5 acetate buffer), the results of which are shown in fig. 6.
The result shows that the dissolution rate of the preparation product taking the crystalline form A of the esomeprazole tenofovir hemifumarate compound as an active ingredient is better than that of the tenofovir monofumarate.
Claims (13)
1. A crystal form A of an esomeprazole tenofovir hemifumarate compound shown in a formula (I) is characterized in that,
The X-ray powder diffraction pattern of the crystal form A has diffraction peaks at the angles of 5.1+/-0.2 DEG, 7.7+/-0.2 DEG, 13.0+/-0.2 DEG, 15.4+/-0.2 DEG, 20.9+/-0.2 DEG and 22.1+/-0.2 DEG of 2 theta.
2. Form a of the eimeril amine tenofovir hemifumarate complex according to claim 1, further comprising an X-ray powder diffraction pattern of form a at least one of 25.0 ± 0.2 ° or 10.2 ± 0.2 ° in 2Θ.
3. Form a of the eimeria tenofovir hemifumarate complex according to claim 2, wherein the X-ray powder diffraction pattern of form a optionally further comprises diffraction peaks at any 2, 3, 4,5,6,7 of 2Θ at 10.5±0.2 °, 10.8±0.2 °, 16.1±0.2 °, 17.0±0.2 °, 19.6±0.2°, 20.4±0.2° and 29.2±0.2°.
4. A crystalline form a of an eimeria tenofovir hemifumarate complex of formula (I), characterized in that the X-ray powder diffraction pattern of form a has diffraction peaks at optionally 6, 8 or 10 of degrees 2Θ at 5.1±0.2°、7.7±0.2°、13.0±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2° and 29.2 ± 0.2 °.
5. Form a of the esomeprazole tenofovir hemifumarate complex according to claim 4, characterized in that the X-ray powder diffraction pattern of form a comprises in 2Θ:
5.1±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°;
7.7±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°;
13.0±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°;
5.1±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
7.7±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°;
13.0±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°;
5.1±0.2°、7.7±0.2°、13.0±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°;
7.7±0.2°、13.0±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°;
13.0±0.2°、15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°;
15.4±0.2°、20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°;
20.9±0.2°、22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2°;
22.1±0.2°、25.0±0.2°、10.2±0.2°、10.5±0.2°、10.8±0.2°、16.1±0.2°、17.0±0.2°、19.6±0.2°、20.4±0.2°、29.2±0.2°.
6. form a of the esomeprazole tenofovir hemifumarate complex according to claim 1, characterized by an X-ray powder diffraction pattern substantially as shown in figure 1.
7. Crystalline form a of the eimeric tenofovir hemi-fumaric acid complex according to any of claims 1-6, prepared by a process comprising the steps of:
① Mixing the esomeprazole tenofovir monofumarate and the esomeprazole tenofovir free base with a solvent at a certain temperature;
② Adding an antisolvent into the solution system to crystallize the solution system;
③ Stirring, filtering and collecting solids to obtain the crystalline form A of the esomeprazole tenofovir hemifumarate compound.
8. The process for the preparation of crystalline form a of esomeprazole tenofovir hemifumarate complex according to claim 7, characterized in that:
The temperature condition of the step ① is 55-70 ℃;
The molar ratio of the eimeric tenofovir monofumarate to the eimeric tenofovir free base is 1:1-1:3; the mass volume ratio of the mixture of the eimeric tenofovir monofumarate and the eimeric tenofovir free base to the solvent is 1g:2 ml-1 g:8ml;
The solvent is selected from cyclic ethers; the reaction time is 1-6 h;
Step ② the antisolvent is selected from a fatty ether or an alkane; the dosage of the antisolvent is 2-7 times of that of the solvent in the step ①;
and ③, stirring for 5-24 hours.
9. The process for the preparation of crystalline form a of esomeprazole tenofovir hemifumarate complex according to claim 7, characterized in that:
The temperature condition of the step ① is 60-65 ℃;
the molar ratio of the eimeric tenofovir monofumarate to the eimeric tenofovir free base is 1:1.1-1:2;
the mass volume ratio of the mixture of the eimeric tenofovir monofumarate and the eimeric tenofovir free base to the solvent is 1g:3 ml-1 g:6ml;
The solvent is selected from one of tetrahydrofuran, 2-methyltetrahydrofuran and 1, 4-dioxane;
The reaction time is 2-5 h;
Step ②, selecting an antisolvent from one of methyl tertiary butyl ether, isopropyl ether and n-heptane; the dosage of the antisolvent is 3-6 times of that of the solvent in the step ①;
And ③, stirring for 8-20 hours.
10. The process for the preparation of crystalline form a of esomeprazole tenofovir hemifumarate complex according to claim 7, characterized in that:
the temperature condition of the step ① is 65 ℃;
the molar ratio of the eimeric tenofovir monofumarate to the eimeric tenofovir free base is 1:1.2-1:1.5; the mass volume ratio of the mixture of the eimeric tenofovir monofumarate and the eimeric tenofovir free base to the solvent is 1g to 4ml;
the solvent is tetrahydrofuran; the reaction time is 2-3 h;
step ②, wherein the antisolvent is isopropyl ether; the dosage of the antisolvent is 4-5 times of that of the solvent in the step ①;
And ③, stirring for 10-18 hours.
11. A pharmaceutical composition comprising a therapeutically effective amount of crystalline form a of the eimeric tenofovir hemi-fumarate complex of any one of claims 1-6, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
12. Use of crystalline form a of the eimeril tenofovir hemi-fumarate complex according to any one of claims 1-6 or the pharmaceutical composition of claim 11 in the manufacture of a medicament for the treatment of hepatitis-related disorders.
13. Form a of the eimeric tenofovir hemifumarate complex according to any one of claims 1-6, or the use according to claim 12, wherein the hepatitis is chronic hepatitis b.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110648580.5A CN113501846B (en) | 2021-06-10 | 2021-06-10 | Eimerosamine tenofovir hemi-fumaric acid compound, crystal form, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110648580.5A CN113501846B (en) | 2021-06-10 | 2021-06-10 | Eimerosamine tenofovir hemi-fumaric acid compound, crystal form, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113501846A CN113501846A (en) | 2021-10-15 |
CN113501846B true CN113501846B (en) | 2024-06-25 |
Family
ID=78010282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110648580.5A Active CN113501846B (en) | 2021-06-10 | 2021-06-10 | Eimerosamine tenofovir hemi-fumaric acid compound, crystal form, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113501846B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101778855A (en) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | Tenofovir disoproxil hemi-fumaric acid co-crystal |
CN103665043A (en) * | 2012-08-30 | 2014-03-26 | 上海源力生物技术有限公司 | Tenofovir prodrug and medical application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104045667A (en) * | 2013-03-14 | 2014-09-17 | 上海卫思化学科技有限公司 | Preparation method of tenofovir disoproxil fumarate hemifumarate |
CN104558035B (en) * | 2013-10-22 | 2017-12-19 | 连云港恒运药业有限公司 | A kind of purification process of tenofovir prodrug |
WO2017037608A1 (en) * | 2015-08-28 | 2017-03-09 | Laurus Labs Private Limited | Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof |
CN106699812A (en) * | 2015-11-12 | 2017-05-24 | 江苏豪森药业集团有限公司 | Method for preparation and purification of tenofovir prodrug |
WO2017203395A1 (en) * | 2016-05-21 | 2017-11-30 | Shilpa Medicare Limited | Crystalline forms of tenofovir alafenamide hemi fumarate |
CN111096954B (en) * | 2018-10-29 | 2022-09-16 | 江苏豪森药业集团有限公司 | A pharmaceutical composition for resisting viral infection and its preparation method |
-
2021
- 2021-06-10 CN CN202110648580.5A patent/CN113501846B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101778855A (en) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | Tenofovir disoproxil hemi-fumaric acid co-crystal |
CN103665043A (en) * | 2012-08-30 | 2014-03-26 | 上海源力生物技术有限公司 | Tenofovir prodrug and medical application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113501846A (en) | 2021-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100661153B1 (en) | Nucleotide analog composition and synthesis method | |
CN106414466B (en) | Tenofovir Chinese mugwort draws phenol amine compound and its preparation method and application | |
JP4452034B2 (en) | Process for preparing adefovir dipivoxil | |
CN105646584B (en) | Tenofovir Chinese mugwort draws phenol amine fumarate crystal form and its preparation method and application | |
JP2010527996A (en) | Tenofovir disoproxil-hemifumarate co-crystal | |
CN112142679B (en) | Gefitinib and vanilloid eutectic methanol solvate and preparation method thereof | |
WO2011095059A1 (en) | Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof | |
CN111406056B (en) | Crystalline 2-amino-2- (hydroxymethyl) propane-1, 3-diol salts of selective ACC inhibitors | |
CN113501846B (en) | Eimerosamine tenofovir hemi-fumaric acid compound, crystal form, preparation method and application thereof | |
TWI718990B (en) | A novel polymorphic form of tenofovir prodrug and its preparation as well as the use thereof | |
US20050182066A1 (en) | Methods for the production of sildenafil base and citrate salt | |
CN101993417A (en) | Stable novel crystal form of dimemorfan phosphate | |
CN106316964B (en) | The polymorph of phenyl amino pyrimidine compounds or its salt | |
CN110128359B (en) | Crystal of uric acid transporter 1 inhibitor and preparation method and application thereof | |
CN108948084B (en) | Tenofovir di-L-amino acid ester and preparation method thereof | |
CA2954491C (en) | Novel salt of tenofovir disoproxil | |
CN104844604A (en) | Preparation method of high purity allopurinol sodium | |
CN116903658A (en) | Nitrogen-containing fused heterocyclic compound crystal form, and preparation method and application thereof | |
CN113072583A (en) | Crystal of tenofovir alafenamide hemifumarate and preparation method thereof | |
JP5589097B2 (en) | Dasatinib polycrystal, preparation method thereof and drug composition | |
CN117510543A (en) | Ai Miti Norafuro Wei Malai acid salt crystal form and preparation method and application thereof | |
CN110938001A (en) | Chlorogenic acid ethanolamine salt and application thereof | |
CN1900078A (en) | Entecavir potassium salt compound and its preparing method and medicine use | |
CN106316963A (en) | Polymorphic substances of morpholinophenylaminopyrimidine compound or salts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |